A brief pubmed search about the topic showed a few studies and reviews on the subject. It appears that Cilostazol is non-inferior to aspirin per one study, and is effective in lowering cerebrovascular events with low rates of bleeding. I did not come across any studies that mention adverse events from using this drug. However, since it is not considered standard of care, it probably should only be used on an experimental basis with documentation as such- if it is used at all. Hope this helps.
Lancet Neurol. 2010 Oct;9(10):959-68. Epub 2010 Sep 15.
Cochrane Database Syst Rev. 2011 Jan 19;1:CD008076
J Stroke Cerebrovasc Dis. 2009 Nov-Dec;18(6):482-90.
No comments:
Post a Comment